Advertisement
Singapore markets closed
  • Straits Times Index

    3,314.14
    +8.12 (+0.25%)
     
  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     
  • Dow

    39,150.33
    +15.53 (+0.04%)
     
  • Nasdaq

    17,689.36
    -32.24 (-0.18%)
     
  • Bitcoin USD

    61,444.49
    -2,936.37 (-4.56%)
     
  • CMC Crypto 200

    1,261.81
    -47.91 (-3.66%)
     
  • FTSE 100

    8,271.88
    +34.16 (+0.41%)
     
  • Gold

    2,337.00
    +5.80 (+0.25%)
     
  • Crude Oil

    81.03
    +0.30 (+0.37%)
     
  • 10-Yr Bond

    4.2570
    +0.0030 (+0.07%)
     
  • Nikkei

    38,804.65
    +208.18 (+0.54%)
     
  • Hang Seng

    18,027.71
    -0.81 (-0.00%)
     
  • FTSE Bursa Malaysia

    1,589.66
    -0.71 (-0.04%)
     
  • Jakarta Composite Index

    6,889.17
    +9.19 (+0.13%)
     
  • PSE Index

    6,272.46
    +113.98 (+1.85%)
     

Why Biohaven Stock Caught Fire This Week

Why Biohaven Stock Caught Fire This Week

Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain was sparked by the company's research and development day presentation held on Wednesday. Highlights from Biohaven's presentation include the unexpected Food and Drug Administration (FDA) regulatory filing for the experimental spinocerebellar ataxia type 3 drug troriluzole, status updates on its closely watched epilepsy program, and a clinical strategy overview for its newly acquired neuroinflammatory asset BHV-8000.